Vincent founder Slava Rubin and Sacra co-founder Jan-Erik Asplund looked at Neuralink, the Elon Musk-founded neurotechnology company. They talked about the company’s growth, strengths, challenges, IPO prospects, and much more.
During the discussion, Slava and Jan-Erik talked about:
- How Neuralink aims to develop implantable technology for brain-computer interfaces.
- That the company has raised over $750 million and is valued at over $10 billion.
- How clinical trials have shown promising results, including a human patient controlling a computer mouse.
- The significant risks associated with the technology, including electrode longevity and immune response.
- Why future revenue projections vary widely based on trial outcomes and market acceptance.
- The ethical implications, including concerns about hacking and public acceptance of brain implants.
- Investment in Neuralink carries high risk but also high potential rewards.
Full Transcript
